Exchange: NASDAQ·Updated 04:28 PM EST

NVCT News

News
all
press releases
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.
Zacks
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.
Zacks
More News
The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 56.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
The consensus price target hints at a 61.5% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Does Nuvectis Pharma, Inc. (NVCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
US stock futures up, Dow futures gain 100+ points. Concentrix Corp (CNXC) shares down 24% after weak Q2 results and lowered FY26 guidance. Other stocks also decline in pre-market trading.read more...
Benzinga
Nuvectis Pharma (NVCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
NVCT stock jumped after Nuvectis expanded its pipeline through a licensing deal with Haisco.read more...
Benzinga
The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 57% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
The average of price targets set by Wall Street analysts indicates a potential upside of 62.5% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04...
MarketBeat

Advertisement|Remove ads.